Guardant Health
GH
#3170
Rank
NZ$6.48 B
Marketcap
$52.50
Share price
0.42%
Change (1 day)
32.68%
Change (1 year)
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.

P/E ratio for Guardant Health (GH)

P/E ratio as of November 2024 (TTM): -6.25

According to Guardant Health 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.24847. At the end of 2022 the company had a P/E ratio of -4.25.

P/E ratio history for Guardant Health from 2018 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-4.25-83%
2021-25.0-49.94%
2020-50.0-46.3%
2019-93.0159.21%
2018-35.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-34.8 457.41%๐Ÿ‡บ๐Ÿ‡ธ USA
-125 1,897.02%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.